{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:45:19Z","timestamp":1784835919684,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04896-0","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:35:33Z","timestamp":1765445733000},"page":"6309-6324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"399","author":[{"given":"Umama","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4273-0827","authenticated-orcid":false,"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif Shahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Moiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ansab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alishba","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaryab","family":"Bacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarar Ahmad Khan","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"4896_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04388-1","author":"U Alam","year":"2025","unstructured":"Alam U, Ali MA, Ansab M et al (2025) Extended reduced versus full-dose treatment with factor Xa inhibitors in patients with venous thromboembolism: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. Naunyn-Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04388-1","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"4896_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","volume":"74","author":"N Antesso","year":"2016","unstructured":"Antesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P et al (2016) Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. J Clin Epidemiol 74:28\u201339","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"4896_CR3","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","volume":"110","author":"M Azizi","year":"2025","unstructured":"Azizi M, Riancho J, Amar L (2025) Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases. J Clin Endocrinol Metab 110(3):e557\u2013e565. https:\/\/doi.org\/10.1210\/clinem\/dgae823","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"4896_CR4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s10741-025-10549-4","volume":"30","author":"CJ Beavers","year":"2025","unstructured":"Beavers CJ, Greene SJ (2025) Hyperkalemia in heart failure with reduced ejection fraction: implications and management. Heart Fail Rev 30(6):1291\u20131305. https:\/\/doi.org\/10.1007\/s10741-025-10549-4","journal-title":"Heart Fail Rev"},{"key":"4896_CR5","doi-asserted-by":"publisher","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, et al (2025) Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. Published online September 13, 2024. https:\/\/doi.org\/10.1093\/eurjpc\/zwae281","DOI":"10.1093\/eurjpc\/zwae281"},{"key":"4896_CR6","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training (n.d.) Accessed January 11, 2025. https:\/\/training.cochrane.org\/handbook"},{"issue":"5","key":"4896_CR7","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2305173","volume":"23","author":"S Corradetti","year":"2022","unstructured":"Corradetti S, Gallo G, Correale M et al (2022) \u03b2-blockers and erectile dysfunction in heart failure. Between myth and reality. Rev Cardiovasc Med 23(5):173. https:\/\/doi.org\/10.31083\/j.rcm2305173","journal-title":"Rev Cardiovasc Med"},{"issue":"7109","key":"4896_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"issue":"9343","key":"4896_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","volume":"360","author":"M Ezzati","year":"2002","unstructured":"Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group (2002) Selected major risk factors and global and regional burden of disease. Lancet 360(9343):1347\u20131360. https:\/\/doi.org\/10.1016\/S0140-6736(02)11403-6","journal-title":"Lancet"},{"key":"4896_CR10","doi-asserted-by":"publisher","unstructured":"GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L et al (2015) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386(10010):2287\u20132323. https:\/\/doi.org\/10.1016\/S0140-6736(15)00128-2","DOI":"10.1016\/S0140-6736(15)00128-2"},{"issue":"4","key":"4896_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1060028016682251","volume":"51","author":"P Hallberg","year":"2017","unstructured":"Hallberg P, Nagy J, Karawajczyk M et al (2017) Comparison of clinical factors between patients with angiotensin-converting enzyme inhibitor-induced angioedema and cough. Ann Pharmacother 51(4):293\u2013300. https:\/\/doi.org\/10.1177\/1060028016682251","journal-title":"Ann Pharmacother"},{"issue":"4","key":"4896_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/s0223-5234(03)00049-7","volume":"38","author":"RW Hartmann","year":"2003","unstructured":"Hartmann RW, M\u00fcller U, Ehmer PB (2003) Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur J Med Chem 38(4):363\u2013366. https:\/\/doi.org\/10.1016\/s0223-5234(03)00049-7","journal-title":"Eur J Med Chem"},{"issue":"5","key":"4896_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/s0025-7125(05)70568-x","volume":"81","author":"J He","year":"1997","unstructured":"He J, Whelton PK (1997) Epidemiology and prevention of hypertension. Med Clin North Am 81(5):1077\u20131097. https:\/\/doi.org\/10.1016\/s0025-7125(05)70568-x","journal-title":"Med Clin North Am"},{"issue":"5","key":"4896_CR14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1161\/hypertensionaha.121.17981","volume":"78","author":"G Jia","year":"2021","unstructured":"Jia G, Sowers JR (2021) Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension 78(5):1197\u20131205. https:\/\/doi.org\/10.1161\/hypertensionaha.121.17981","journal-title":"Hypertension"},{"issue":"1","key":"4896_CR15","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L (2017) 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 234(1):T125\u2013T140. https:\/\/doi.org\/10.1530\/JOE-16-0600","journal-title":"J Endocrinol"},{"key":"4896_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1472-6904-11-4","volume":"11","author":"J Lachaine","year":"2011","unstructured":"Lachaine J, Beauchemin C, Ramos E (2011) Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol 11:4. https:\/\/doi.org\/10.1186\/1472-6904-11-4","journal-title":"BMC Clin Pharmacol"},{"issue":"12","key":"4896_CR17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin LJ, Rodman D, Luther JM et al (2023) Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial. JAMA 330(12):1140\u20131150. https:\/\/doi.org\/10.1001\/jama.2023.16029","journal-title":"JAMA"},{"key":"4896_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2022.108809","volume":"347","author":"J Leete","year":"2022","unstructured":"Leete J, Wang C, L\u00f3pez-Hern\u00e1ndez FJ, Layton AT (2022) Determining risk factors for triple whammy acute kidney injury. Math Biosci 347:108809. https:\/\/doi.org\/10.1016\/j.mbs.2022.108809","journal-title":"Math Biosci"},{"issue":"11","key":"4896_CR19","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/acr.24070","volume":"72","author":"JW Liew","year":"2019","unstructured":"Liew JW, Ward MM, Reveille JD et al (2019) Nonsteroidal antiinflammatory drug use and association with incident hypertension in ankylosing spondylitis. Arthritis Care Res 72(11):1645\u20131652. https:\/\/doi.org\/10.1002\/acr.24070","journal-title":"Arthritis Care Res"},{"issue":"6","key":"4896_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN et al (2016) Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134(6):441\u2013450. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018912","journal-title":"Circulation"},{"key":"4896_CR21","doi-asserted-by":"publisher","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2021) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants [published correction appears in Lancet. 2022 Feb 5;399(10324):520. 10.1016\/S0140-6736(22)00061-7.]. Lancet 398(10304):957\u2013980. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1","DOI":"10.1016\/S0140-6736(21)01330-1"},{"key":"4896_CR22","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj 372","DOI":"10.1136\/bmj.n71"},{"issue":"6","key":"4896_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.semnephrol.2011.09.009","volume":"31","author":"BF Palmer","year":"2011","unstructured":"Palmer BF (2011) Metabolic complications associated with use of diuretics. Semin Nephrol 31(6):542\u2013552. https:\/\/doi.org\/10.1016\/j.semnephrol.2011.09.009","journal-title":"Semin Nephrol"},{"key":"4896_CR24","doi-asserted-by":"publisher","unstructured":"Pitt B, Remme W, Zannad F, et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003 May 29;348(22):2271]. N Engl J Med 348(14):1309\u20131321. https:\/\/doi.org\/10.1056\/NEJMoa030207","DOI":"10.1056\/NEJMoa030207"},{"key":"4896_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04482-4","author":"S Rath","year":"2025","unstructured":"Rath S, Alam U, Kashif A et al (2025) Intravenous thrombolysis as an adjunct to endovascular thrombectomy in acute basilar artery occlusion: a GRADE-assessed systematic review and meta-analysis. Naunyn-Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04482-4","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"4896_CR26","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/ckj\/sfad139","volume":"16","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Iatridi F, Ferro C et al (2023) Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). Clin Kidney J 16(11):1885\u20131907. https:\/\/doi.org\/10.1093\/ckj\/sfad139","journal-title":"Clin Kidney J"},{"key":"4896_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.9413","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C et al (2025) Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.9413","journal-title":"JAMA"},{"issue":"1","key":"4896_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/ds.DS-D-22-00154","volume":"41","author":"SC Shao","year":"2023","unstructured":"Shao SC, Kuo LT, Huang YT, Lai PC, Chi CC (2023) Using grading of recommendations assessment, development, and evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: a quick tutorial. Dermatol Sin 41(1):3","journal-title":"Dermatol Sin"},{"issue":"8","key":"4896_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70000","volume":"17","author":"H Shimizu","year":"2024","unstructured":"Shimizu H, Tortorici MA, Ohta Y et al (2024) First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor. Clin Transl Sci 17(8):e70000. https:\/\/doi.org\/10.1111\/cts.70000","journal-title":"Clin Transl Sci"},{"issue":"4","key":"4896_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1524-6175.2003.02402.x","volume":"5","author":"D Sica","year":"2003","unstructured":"Sica D (2003) Calcium channel blocker-related periperal edema: can it be resolved? J Clin Hypertens (Greenwich) 5(4):291\u2013297. https:\/\/doi.org\/10.1111\/j.1524-6175.2003.02402.x","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"4896_CR31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4103\/jfmpc.jfmpc_1419_24","volume":"14","author":"J Singh","year":"2025","unstructured":"Singh J, Iqbal SA, Mohammed TI et al (2025) Prevalence and associated risk factors of hypertension in rural and urban areas of Punjab: a cross-sectional study. J Family Med Primary Care 14(2):757\u2013761. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1419_24","journal-title":"J Family Med Primary Care"},{"key":"4896_CR32","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. bmj 366","DOI":"10.1136\/bmj.l4898"},{"key":"4896_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.770375","volume":"13","author":"A Tsilosani","year":"2022","unstructured":"Tsilosani A, Gao C, Zhang W (2022) Aldosterone-regulated sodium transport and blood pressure. Front Physiol 13:770375. https:\/\/doi.org\/10.3389\/fphys.2022.770375","journal-title":"Front Physiol"},{"key":"4896_CR34","doi-asserted-by":"publisher","unstructured":"Whelton PK, Carey RM, Aronow WS et al (2017) ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines [published correction appears in Hypertension. 2018 Jun;71(6):e136-e139. 10.1161\/HYP.0000000000000075.] [published correction appears in Hypertension. 2018 Sep;72(3):e33. 10.1161\/HYP.0000000000000080.]. Hypertension. 2018;71(6):1269\u20131324. https:\/\/doi.org\/10.1161\/HYP.0000000000000066","DOI":"10.1161\/HYP.0000000000000066"},{"issue":"11","key":"4896_CR35","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/ndt\/gfad101","volume":"38","author":"R Whitlock","year":"2023","unstructured":"Whitlock R, Leon SJ, Manacsa H et al (2023) The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 38(11):2503\u20132516. https:\/\/doi.org\/10.1093\/ndt\/gfad101","journal-title":"Nephrol Dial Transplant"},{"issue":"10008","key":"4896_CR36","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386(10008):2059\u20132068. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3","journal-title":"Lancet"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04896-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04896-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04896-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:16:34Z","timestamp":1776312994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04896-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4896"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04896-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this is a systematic review and meta-analysis of published results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have reviewed the final draft and agree to the publication of the manuscript in its current form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}